Prof Yago Nieto speaks to ecancer about modified immune Cells (AFM13-NK) and a monoclonal antibody (AFM13) in treating patients with recurrent or refractory CD30 positive Hodgkin or non-Hodgkin lymphomas.
Initially Prof Nieto talks about the background and the methodology of the study. This study evaluated the tolerability and activity of this novel adoptive cellular immunotherapy using allogeneic natural killer cells, whose intact killing capacity can be further increased by cytokine pre-activation and whose numbers can be largely expanded in the lab.
He then explains the results of this trial. Across all dose levels, 53 percent of patients experienced a complete response, 37 percent experienced a partial response, and 11 percent had progressive disease.
Prof Nieto says that the preliminary results from this study indicate excellent tolerability and high activity and warrant further investigation of this approach. He concludes by discussing what the future impact of these results can be on the treatment of lymphomas.